A prespecified FLOW subgroup analysis tested whether semaglutide’s kidney and cardiovascular benefit held with or without baseline SGLT2 inhibitor use in type 2 diabetes and CKD. PICO summary and expert commentary.
Browsing: Semaglutide
Prespecified secondary analysis of the pooled STEP-HFpEF trials finds semaglutide 2.4 mg improves heart failure symptoms similarly in women and men, with greater weight loss in women. PICO summary and expert commentary.
A phase 1 trial characterising oral semaglutide pharmacokinetics, pharmacodynamics and tolerability in 32 healthy Chinese adults. PICO summary and expert commentary.
A prespecified analysis of the SELECT trial shows once-weekly semaglutide produced a placebo-subtracted weight reduction of 10.2% sustained to 208 weeks in adults with cardiovascular disease and overweight or obesity but without diabetes. PICO summary and expert commentary.
A pre-specified analysis of the SELECT trial assessing whether once-weekly semaglutide 2.4 mg improves kidney outcomes in adults with overweight or obesity and cardiovascular disease, without diabetes. PICO summary and expert commentary.
A prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials showing that once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
In the FLOW trial, once-weekly semaglutide lowered major kidney disease events by 24% in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.
A prespecified secondary analysis of the STEP-HFpEF programme found that once-weekly semaglutide 2.4 mg lowered NT-proBNP and produced larger symptom gains in patients with higher baseline NT-proBNP. PICO summary and expert commentary.
A post hoc analysis of the SURPASS-2 phase 3 trial comparing tirzepatide and semaglutide on HOMA2 markers of beta-cell function and insulin sensitivity in type 2 diabetes. PICO summary and expert commentary.
Pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials of semaglutide 2.4 mg in obesity-related HFpEF, with PICO summary and expert commentary.